Cargando…
Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide.
Metastatic testicular germ cell tumours are cured in approximately 85% of patients using cisplatin-based combination chemotherapy. Patients who fail to respond have a poor prognosis, and there is a need for more effective treatments for cisplatin-resistant disease. In this study, it is shown that tw...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033767/ https://www.ncbi.nlm.nih.gov/pubmed/7734313 |
_version_ | 1782136909554778112 |
---|---|
author | Pera, M. F. Köberle, B. Masters, J. R. |
author_facet | Pera, M. F. Köberle, B. Masters, J. R. |
author_sort | Pera, M. F. |
collection | PubMed |
description | Metastatic testicular germ cell tumours are cured in approximately 85% of patients using cisplatin-based combination chemotherapy. Patients who fail to respond have a poor prognosis, and there is a need for more effective treatments for cisplatin-resistant disease. In this study, it is shown that two of four cell lines derived from human non-seminomatous testicular germ cell tumours are exceptionally sensitive to temozolomide, a new imidazotetrazine which can cross the blood-brain barrier in mice. In addition, three pairs of cisplatin-resistant sublines show little cross-resistance to temozolomide. These data suggest that temozolomide might have activity against non-seminomatous testicular germ cell tumours which have relapsed following cisplatin-containing chemotherapy, and could have a role in the treatment of patients with metastatic lesions in the brain. |
format | Text |
id | pubmed-2033767 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1995 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-20337672009-09-10 Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide. Pera, M. F. Köberle, B. Masters, J. R. Br J Cancer Research Article Metastatic testicular germ cell tumours are cured in approximately 85% of patients using cisplatin-based combination chemotherapy. Patients who fail to respond have a poor prognosis, and there is a need for more effective treatments for cisplatin-resistant disease. In this study, it is shown that two of four cell lines derived from human non-seminomatous testicular germ cell tumours are exceptionally sensitive to temozolomide, a new imidazotetrazine which can cross the blood-brain barrier in mice. In addition, three pairs of cisplatin-resistant sublines show little cross-resistance to temozolomide. These data suggest that temozolomide might have activity against non-seminomatous testicular germ cell tumours which have relapsed following cisplatin-containing chemotherapy, and could have a role in the treatment of patients with metastatic lesions in the brain. Nature Publishing Group 1995-05 /pmc/articles/PMC2033767/ /pubmed/7734313 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Pera, M. F. Köberle, B. Masters, J. R. Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide. |
title | Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide. |
title_full | Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide. |
title_fullStr | Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide. |
title_full_unstemmed | Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide. |
title_short | Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide. |
title_sort | exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033767/ https://www.ncbi.nlm.nih.gov/pubmed/7734313 |
work_keys_str_mv | AT peramf exceptionalsensitivityoftesticulargermcelltumourcelllinestothenewanticanceragenttemozolomide AT koberleb exceptionalsensitivityoftesticulargermcelltumourcelllinestothenewanticanceragenttemozolomide AT mastersjr exceptionalsensitivityoftesticulargermcelltumourcelllinestothenewanticanceragenttemozolomide |